Trials / Unknown
UnknownNCT03900325
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis
A Single-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bird Rock Bio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics, and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimacimab | 2.5 mg/kg |
| DRUG | Placebo | 0.9% sodium chloride |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2020-01-01
- Completion
- 2020-04-01
- First posted
- 2019-04-03
- Last updated
- 2020-01-18
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03900325. Inclusion in this directory is not an endorsement.